Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

C5a structural requirements for neutrophil receptor interaction.

K W Mollison1, T A Fey, R A Krause

  • 1Immunoscience Research Area, Abbott Laboratories, Abbott Park, IL 60064.

Agents and Actions. Supplements
|January 1, 1991
PubMed
Summary

Researchers modified complement component 5a (C5a) to understand its effects on immune cell receptors. A specific substitution significantly enhanced C5a's activity, offering insights into immune response modulation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models.

Journal of medicinal chemistry·2001
Same author

Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds.

The Journal of biological chemistry·2001
Same author

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.

Journal of medicinal chemistry·2000
Same author

Bipartite determinants of DNA-binding specificity of plant basic leucine zipper proteins.

Plant molecular biology·1999
Same author

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
Same author

Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.

Journal of medicinal chemistry·1999

Area of Science:

  • Immunology
  • Biochemistry

Background:

  • Complement component 5a (C5a) is a potent anaphylatoxin that plays a crucial role in innate and adaptive immunity.
  • C5a mediates its effects by binding to specific receptors on immune cells, primarily polymorphonuclear leukocytes (PMNLs).
  • Understanding C5a-receptor interactions is vital for developing targeted immunomodulatory therapies.

Purpose of the Study:

  • To investigate the impact of C5a modifications on PMNL receptor binding and activation.
  • To identify key residues and regions within C5a that influence its biological activity.
  • To enhance the potency and efficacy of C5a-derived agonists.

Main Methods:

  • Site-directed mutagenesis was employed to introduce specific amino acid substitutions in C5a.
  • Synthetic peptides corresponding to C5a fragments were synthesized and tested.

Related Experiment Videos

  • PMNL chemokinesis and myeloperoxidase (MPO) release assays were performed to assess C5a activity.
  • Receptor binding assays were conducted to evaluate C5a-receptor interactions.

    • Main Results:

    • Modifications at the C-terminus of C5a influenced receptor binding and PMNL activation.
    • A synthetic peptide (C5a 19-30) showed weak inhibition of C5a binding.
    • A C-terminal octapeptide, a full agonist, exhibited significantly improved potency upon substitution of histidine at position 67 with phenylalanine (Phe).
    • A Phe point mutation at His67 enhanced the activity of the full recombinant C5a protein.

    Conclusions:

    • Key C-terminal residues, including Lys19-20, are important for C5a function.
    • Specific amino acid substitutions, particularly Phe at position 67, can markedly enhance C5a agonist potency.
    • These findings provide a basis for designing more effective C5a-based therapeutics for immune modulation.